Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iRadimed Corporation stock logo
IRMD
iRadimed
$56.69
-1.3%
$57.62
$42.34
$63.29
$720.81M0.9144,166 shs30,893 shs
SiBone stock logo
SIBN
SiBone
$16.62
-0.7%
$18.22
$11.70
$20.05
$708.26M0.93391,531 shs296,134 shs
Stereotaxis Inc. stock logo
STXS
Stereotaxis
$2.32
-2.5%
$2.18
$1.54
$2.72
$199.52M1.44341,280 shs399,166 shs
Westaim Corp. stock logo
WEDXF
Westaim
$21.91
-0.6%
$22.86
$16.62
$25.98
$735.19M0.21,989 shs1,903 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iRadimed Corporation stock logo
IRMD
iRadimed
0.00%-1.53%-3.01%+9.50%+22.76%
SiBone stock logo
SIBN
SiBone
0.00%-3.37%-0.36%+20.00%-2.86%
Stereotaxis Inc. stock logo
STXS
Stereotaxis
0.00%+3.11%+2.65%+25.41%+22.11%
Westaim Corp. stock logo
WEDXF
Westaim
0.00%-2.88%-5.93%+1.48%+650.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iRadimed Corporation stock logo
IRMD
iRadimed
4.5292 of 5 stars
3.53.02.54.40.03.31.9
SiBone stock logo
SIBN
SiBone
3.8384 of 5 stars
3.52.00.03.31.22.50.6
Stereotaxis Inc. stock logo
STXS
Stereotaxis
0.0558 of 5 stars
0.00.00.00.00.01.70.6
Westaim Corp. stock logo
WEDXF
Westaim
0.4799 of 5 stars
0.05.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iRadimed Corporation stock logo
IRMD
iRadimed
3.00
Buy$72.0027.01% Upside
SiBone stock logo
SIBN
SiBone
3.00
Buy$22.5035.38% Upside
Stereotaxis Inc. stock logo
STXS
Stereotaxis
0.00
N/AN/AN/A
Westaim Corp. stock logo
WEDXF
Westaim
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest STXS, WEDXF, IRMD, and SIBN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
SiBone stock logo
SIBN
SiBone
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iRadimed Corporation stock logo
IRMD
iRadimed
$73.24M9.85$1.58 per share35.83$6.85 per share8.28
SiBone stock logo
SIBN
SiBone
$167.18M4.24N/AN/A$3.98 per share4.18
Stereotaxis Inc. stock logo
STXS
Stereotaxis
$26.92M7.41N/AN/A$0.07 per share33.14
Westaim Corp. stock logo
WEDXF
Westaim
$17.04M43.15N/AN/A$23.28 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iRadimed Corporation stock logo
IRMD
iRadimed
$19.23M$1.5536.5728.35N/A26.33%23.28%20.59%7/30/2025 (Estimated)
SiBone stock logo
SIBN
SiBone
-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)
Stereotaxis Inc. stock logo
STXS
Stereotaxis
-$24.05M-$0.28N/AN/AN/A-92.19%-325.86%-56.55%8/11/2025 (Estimated)
Westaim Corp. stock logo
WEDXF
Westaim
-$16.18M-$2.17N/AN/A-253.76%-9.36%-8.82%8/12/2025 (Estimated)

Latest STXS, WEDXF, IRMD, and SIBN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Stereotaxis Inc. stock logo
STXS
Stereotaxis
-$0.07N/AN/AN/A$7.75 millionN/A
8/7/2025Q2 2025
iRadimed Corporation stock logo
IRMD
iRadimed
$0.45N/AN/AN/AN/AN/A
8/4/2025Q2 2025
SiBone stock logo
SIBN
SiBone
-$0.19N/AN/AN/A$48.12 millionN/A
5/14/2025Q1 2025
Westaim Corp. stock logo
WEDXF
Westaim
-$0.0316-$0.34-$0.3084-$0.34$1.34 million($4.70) million
5/5/2025Q1 2025
SiBone stock logo
SIBN
SiBone
-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iRadimed Corporation stock logo
IRMD
iRadimed
$0.681.20%N/A43.87%1 Years
SiBone stock logo
SIBN
SiBone
N/AN/AN/AN/AN/A
Stereotaxis Inc. stock logo
STXS
Stereotaxis
N/AN/AN/AN/AN/A
Westaim Corp. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Latest STXS, WEDXF, IRMD, and SIBN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
iRadimed Corporation stock logo
IRMD
iRadimed
quarterly$0.171.3%5/20/20255/20/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iRadimed Corporation stock logo
IRMD
iRadimed
N/A
8.87
7.62
SiBone stock logo
SIBN
SiBone
0.21
8.53
7.26
Stereotaxis Inc. stock logo
STXS
Stereotaxis
N/A
1.07
0.66
Westaim Corp. stock logo
WEDXF
Westaim
N/A
11.40
11.40

Institutional Ownership

CompanyInstitutional Ownership
iRadimed Corporation stock logo
IRMD
iRadimed
92.34%
SiBone stock logo
SIBN
SiBone
98.11%
Stereotaxis Inc. stock logo
STXS
Stereotaxis
45.35%
Westaim Corp. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
iRadimed Corporation stock logo
IRMD
iRadimed
36.80%
SiBone stock logo
SIBN
SiBone
4.00%
Stereotaxis Inc. stock logo
STXS
Stereotaxis
17.77%
Westaim Corp. stock logo
WEDXF
Westaim
4.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
iRadimed Corporation stock logo
IRMD
iRadimed
11012.72 million8.04 millionOptionable
SiBone stock logo
SIBN
SiBone
35042.62 million40.91 millionOptionable
Stereotaxis Inc. stock logo
STXS
Stereotaxis
13086.00 million70.72 millionNot Optionable
Westaim Corp. stock logo
WEDXF
Westaim
733.56 million32.14 millionNot Optionable

Recent News About These Companies

The Westaim Corporation Reports Q1 2025 Results
Westaim completes acquisition of ManhattanLife
The Westaim Corp WEDXD
Westaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)
The Westaim Corporation appoints CRO
Westaim Corporation: A Bargain In The Asset Management World
Westaim Corporation: Still Undervalued Based On NAV
The Westaim Corporation (WEDXF)
Westaim: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

iRadimed stock logo

iRadimed NASDAQ:IRMD

$56.69 -0.76 (-1.32%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$56.52 -0.16 (-0.29%)
As of 07/18/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

SiBone stock logo

SiBone NASDAQ:SIBN

$16.62 -0.11 (-0.66%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$16.63 +0.01 (+0.06%)
As of 07/18/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Stereotaxis stock logo

Stereotaxis NYSEAMERICAN:STXS

$2.32 -0.06 (-2.52%)
Closing price 07/18/2025 04:10 PM Eastern
Extended Trading
$2.32 0.00 (0.00%)
As of 07/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Westaim stock logo

Westaim OTCMKTS:WEDXF

$21.91 -0.14 (-0.62%)
As of 07/18/2025 03:34 PM Eastern

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.